India  

COVAXIN

Latest news and video coverage curated from trusted media outlets

0
shares
ShareTweetSavePostSend
 

You Might Like


Bharat Biotech founder Dr Krishna Ella awarded INSA fellowship for 2025

Dr Krishna Ella, co-founder of Bharat Biotech, has been awarded the prestigious INSA India fellowship for 2025 for his significant contributions to vaccine technology and biotechnology. His work led to..
IndiaTimes - Published

Bharat Biotech sues BHU researchers over Covaxin study

Bharat Biotech has taken legal action against 11 BHU researchers and the journal Drug Safety over a study on Covaxin's side effects. Alleging defamation, Bharat Biotech seeks a permanent injunction and..
IndiaTimes - Published

ICMR slams BHU's Covaxin study, says it wasn't part of it

Indian Council of Medical Research criticizes a recently-published study on Covaxin's safety analysis for poor methodology. The study wrongly acknowledges ICMR. Director Rajiv Bahl clarifies the lack..
IndiaTimes - Published

1 in 3 Covaxin recipients hit by adverse events: Study

Nearly one-third of Covaxin recipients experienced adverse events of special interest within a year, including respiratory, skin, and musculoskeletal issues. The study also highlighted menstrual..
IndiaTimes - Published

Covaxin had much lower adverse effects and overall favourable short-term safety profile in adolescents: Study

Bharat Biotech’s indigenously developed Covid-19 vaccine Covaxin was overall found to have “much lower” AEFI (adverse effects following immunisation) rates in adolescents with a favourable..
IndiaTimes - Published

Over 30% Covaxin takers suffered from health issues after 1 year: Report

A study from BHU analyzing the lasting impacts of Bharat Biotech's Covaxin found nearly a third of recipients reported adverse events of special interest (AESI). Among 926 participants, viral upper..
IndiaTimes - Published

Bharat Biotech stresses on Covaxin’s safety record after AstraZeneca admits to Covishield causing rare clotting side effects

Following AstraZeneca's acknowledgment in a UK court that its Covid-19 vaccine triggered a rare side effect—Thrombosis with Thrombocytopenia Syndrome (TTS), Hyderabad-based vaccine manufacturer..
IndiaTimes - Published

What to watch on OTT this week

Explore a diverse range of content on OTT this week, from the hilarious banter of Koffee with Karan featuring Varun Dhawan and Sidharth Malhotra to the emotional rollercoaster of 'Aam Aadmi Family'..
IndiaTimes - Published

The Vaccine War script to be a featured in Oscar library

Vivek Agnihotri helmed 'The Vaccine War' has been invited by the Academy for their library. The Academy of Motion Picture Arts and Sciences reached out to the filmmaker, expressing interest in..
IndiaTimes - Published

Vivek announces BOGO for The Vaccine War

Vivek Agnihotri, director of 'The Vaccine War,' has announced a 'buy 1 get 1' ticket offer for the movie. The film has been doing well at the box office and Agnihotri wants to show appreciation to the..
IndiaTimes - Published

The Vaccine War struggles at the BO

Directed by Vivek Agnihotri, The Vaccine War is based on the book ‘Going Viral’ by Prof Balram Bhargava, Director General – Indian Council of Medical Research (ICMR). It talks about the..
IndiaTimes - Published

The Vaccine War BO day 1: the movie starts slow

'The Vaccine War' is touted to be India’s first ‘bio-science’ film as it tries to present the story of the scientists who developed India’s Covid-19 vaccine, Covaxin, during the pandemic.
IndiaTimes - Published

Covovax for adults to reach metros in a week: SII

Serum Institute of India’s CEO Adar Poonawalla told TOI on Friday that doses of Covovax — Covid booster shot for adults — would reach major cities in four to five days, while a Bharat Biotech..
IndiaTimes - Published

Covid jab Covovax as heterologous booster to be available on CoWIN soon; to cost Rs 225 per dose

Covovax can be administered to those who have already vaccinated with Covishield or Covaxin. The Drugs Controller General of India (DCGI) on January 16 had approved the market authorisation for Covovax..
IndiaTimes - Published

Amid rising viral cases, Bharat Biotech working on H3N2 vaccine

Amid rising cases of H3N2 influenza virus in the country and reports of some deaths too, Hyderabad-based vaccine maker Bharat Biotech, which developed the indigenous Covaxin and intranasal vaccine..
IndiaTimes - Published

Serum Institute seeks inclusion of Covid jab Covovax in CoWIN portal as heterologous booster dose for adults

Covid-19 vaccine India: The Drug Controller General of India (DCGI) on January 16 approved market authorisation for Covovax as a heterologous booster dose for adults who have been administered two..
Zee News - Published

Drug panel favours nod for Covovax as Covid booster

An expert panel of the central drug regulatory authority has recommended market authorisation for Serum Institute of India’s Covid vaccine, Covovax, as a heterologous booster dose for adults who have..
IndiaTimes - Published

Covovax may get approval as heterologous booster

The government may decide on allowing Serum Institute of India’s (SII) Covovax as a heterologous booster dose, meaning it can be used for people who have taken either Covishield or Covaxin for..
IndiaTimes - Published

Ocugen announces positive top-line data for Covaxin in US trials


newKerala.com - Published

Delhi HC makes Bharat Biotech, Centre parties in pleas seeking details on Covaxin


newKerala.com - Published

Ocugen-Bharat Biotech Covid vaccine Covaxin meets main goals in US trial

Ocugen Inc said on Monday the Covid-19 vaccine developed by its Indian partner Bharat Biotech International Ltd met the main goals of a trial in the United States. The vaccine, sold under brand name..
IndiaTimes - Published